Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer
- PMID: 9469326
- DOI: 10.1200/JCO.1998.16.2.434
Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer
Abstract
Purpose: The possibility that epoetin beta (EPO) could increase hemoglobin (B-Hb) levels and improve quality of life (QoL) in patients with advanced gastrointestinal cancers was investigated.
Patients and methods: One hundred patients with gastric, pancreatic, biliary, or colorectal cancers and subnormal B-Hb levels were included in a randomized study to test low-dose EPO (2,000 U subcutaneously thrice weekly [2,000 group]) against a higher dose (10,000 U times three [10,000 group]). Eighty-four patients were treated with chemotherapy. QoL was evaluated using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 instrument.
Results: At baseline, mean B-Hb was 108 g/L with no difference between the groups. In the 10,000 group, an increase in B-Hb (>10 g/L) was seen in 30 (73%) patients treated with chemotherapy, after a median of 4 weeks, whereas a corresponding increase in the 2,000 group was seen in 15 (30%) patients after a median of 10 weeks (P < .001). A difference in the proportion of responders (five of eight v one of eight) was also seen in the group of patients not treated with chemotherapy. The proportion of responders was independent of baseline endogenous serum EPO level or observed/predicted log10 serum (S)-EPO levels. Patients who demonstrated improved B-Hb levels also showed improvements in QoL parameters. Tumor response was usually also associated with QoL improvements.
Conclusion: Treatment with EPO at a dose of 10,000 U thrice weekly can rapidly and safely increase B-Hb levels in a high proportion of patients with advanced gastrointestinal cancers. QoL is influenced by the B-Hb increase, but also by the course of the underlying malignancy. It is therefore difficult to define clearly the clinical relevance of the B-Hb increase as such.
Similar articles
-
Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.J Med Assoc Thai. 2005 May;88(5):607-12. J Med Assoc Thai. 2005. PMID: 16149676 Clinical Trial.
-
Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study.Hematology. 2007 Dec;12(6):533-41. doi: 10.1080/10245330701521572. Hematology. 2007. PMID: 17852440 Clinical Trial.
-
Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.Pediatr Hematol Oncol. 2011 Sep;28(6):461-8. doi: 10.3109/08880018.2011.570857. Epub 2011 Jun 27. Pediatr Hematol Oncol. 2011. PMID: 21707225
-
Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.Oncology. 2005;68 Suppl 1:22-32. doi: 10.1159/000083130. Oncology. 2005. PMID: 15855813 Review.
-
Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours.Med Oncol. 1998 Aug;15 Suppl 1:S19-28. Med Oncol. 1998. PMID: 9785333 Review.
Cited by
-
Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma.Ann Surg. 2006 Feb;243(2):189-95. doi: 10.1097/01.sla.0000197382.43208.a5. Ann Surg. 2006. PMID: 16432351 Free PMC article.
-
Anemia and quality of life including anemia-related symptoms in patients with solid tumors in clinical practice.Med Oncol. 2007;24(1):95-102. doi: 10.1007/BF02685909. Med Oncol. 2007. PMID: 17673818
-
Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study.Ann Surg. 2003 Mar;237(3):417-21. doi: 10.1097/01.SLA.0000055275.38740.56. Ann Surg. 2003. PMID: 12616127 Free PMC article. Clinical Trial.
-
Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.Drugs. 2004;64(3):323-46. doi: 10.2165/00003495-200464030-00006. Drugs. 2004. PMID: 14871172 Review.
-
Clinical and economic impact of epoetins in cancer care.Pharmacoeconomics. 2004;22(16):1029-45. doi: 10.2165/00019053-200422160-00001. Pharmacoeconomics. 2004. PMID: 15524492 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials